Stifel’s weekly biopharma update, with data partly compiled by DealForma, highlights industry uncertainty from U.S. Election volatility, steady IPO activity, subdued M&A, and promising obesity drug developments, with new research linking sugar addiction to obesity management. Check out Stifel’s report.
